Condition
Philadelphia-Negative ALL
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06287528Phase 1RecruitingPrimary
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
NCT06250959Phase 2Recruiting
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
NCT04334993Phase 2UnknownPrimary
Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
Showing all 3 trials